Oxaliplatin-based regimens (FOLFOX or CAPOX) or irinotecan-based regimens (FOLFIRI or CAPIRI) plus the vascular endothelial growth factor (VEGF) inhibitor bevacizumab as an alternative option in first-line treatment for patients with advanced colon cancer (Cervantes et al., 2023). The gene discussed is VEGFA; the disease is malignant colon neoplasm.